Similar articles

• Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin.

  Krishan A, Sridhar KS, Mou C, Stein WD, Lyubimov E, Hu YP, Fernandez H. Krishan A, et al. Clin Cancer Res. 2000 Apr;6(4):1508-17. Clin Cancer Res. 2000. PMID: 10778983 Clinical Trial.
• Dipyridamole increases the cytotoxicity of cisplatin in human larynx cancer cells in vitro.

  Rodrigues M, Barbosa F Jr, Perussi JR. Rodrigues M, et al. Braz J Med Biol Res. 2004 Apr;37(4):591-9. doi: 10.1590/s0100-879x2004000400017. Epub 2004 Mar 23. Braz J Med Biol Res. 2004. PMID: 15064823
• Potentiation of some anticancer agents by dipyridamole against drug-sensitive and drug-resistant cancer cell lines.

  Asoh K, Saburi Y, Sato S, Nogae I, Kohno K, Kuwano M. Asoh K, et al. Jpn J Cancer Res. 1989 May;80(5):475-81. doi: 10.1111/j.1349-7006.1989.tb02339.x. Jpn J Cancer Res. 1989. PMID: 2568984 Free PMC article.
• Extended-release dipyridamole/aspirin.

  Hervey PS, Goa KL. Hervey PS, et al. Drugs. 1999 Sep;58(3):469-75; discussion 476-7. doi: 10.2165/00003495-199958030-00007. Drugs. 1999. PMID: 10493274 Review.
• Aggrenox: a fixed-dose combination of aspirin and dipyridamole.

  Lenz TL, Hilleman DE. Lenz TL, et al. Ann Pharmacother. 2000 Nov;34(11):1283-90. doi: 10.1345/aph.10079. Ann Pharmacother. 2000. PMID: 11098344 Review.